Kyverna Therapeutics, Inc. Operating Lease Cost
Kyverna Therapeutics, Inc. (KYTX) reported Operating Lease Cost of $619.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- Kyverna Therapeutics, Inc. operating lease, cost for the quarter ending 2026-06-30 was $619.00K, a 27.18% decline year-over-year.
- Kyverna Therapeutics, Inc. operating lease, cost for the quarter ending 2026-03-31 was $763.00K, a 10.24% decline year-over-year.
- Kyverna Therapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $863.00K, a 1.05% increase year-over-year.
- Kyverna Therapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $850.00K, a 0.47% decline year-over-year.
- Kyverna Therapeutics, Inc. operating lease, cost for fiscal 2025 was $3.41M, a 4.95% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. operating lease, cost for fiscal 2024 was $3.25M, a 33.88% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. operating lease, cost for fiscal 2023 was $2.43M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $619.00K 10-Q · filed 2026-08-11 | $1.38M 10-Q · filed 2026-08-11 | $2.25M derived: sum of 3 quarters · filed 2026-08-11 | $3.10M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $763.00K 10-Q · filed 2026-05-12 | $1.63M derived: sum of 2 quarters · filed 2026-05-12 | $2.48M derived: sum of 3 quarters · filed 2026-05-12 | $3.33M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $863.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.71M derived: sum of 2 quarters · filed 2026-03-26 | $2.56M derived: sum of 3 quarters · filed 2026-08-11 | $3.41M 10-K · filed 2026-03-26 | |
| 2025-09-30 | $850.00K 10-Q · filed 2025-11-12 | $1.70M derived: sum of 2 quarters · filed 2026-08-11 | $2.55M 10-Q · filed 2025-11-12 | $3.40M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $850.00K 10-Q · filed 2026-08-11 | $1.70M 10-Q · filed 2026-08-11 | $2.55M derived: sum of 3 quarters · filed 2026-08-11 | $3.41M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $850.00K 10-Q · filed 2026-05-12 | $900.00K 10-Q · filed 2025-05-13 | $1.70M derived: sum of 2 quarters · filed 2026-05-12 | $2.56M derived: sum of 3 quarters · filed 2026-05-12 | $3.41M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $854.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.71M derived: sum of 2 quarters · filed 2026-03-26 | $2.56M derived: sum of 3 quarters · filed 2026-03-26 | $3.25M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $854.00K 10-Q · filed 2025-11-12 | $1.71M derived: sum of 2 quarters · filed 2025-11-12 | $2.40M 10-Q · filed 2025-11-12 | $3.02M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $854.00K 10-Q · filed 2025-08-12 | $1.54M 10-Q · filed 2025-08-12 | $2.16M derived: sum of 3 quarters · filed 2025-08-12 | $2.76M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $700.00K 10-Q · filed 2025-05-13 | $689.00K 10-Q · filed 2024-05-14 | $1.31M derived: sum of 2 quarters · filed 2025-05-13 | $1.91M derived: sum of 3 quarters · filed 2025-05-13 | $2.52M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $608.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.21M derived: sum of 2 quarters · filed 2025-03-27 | $1.82M derived: sum of 3 quarters · filed 2025-03-27 | $2.43M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $602.00K 10-Q · filed 2024-11-13 | $1.21M derived: sum of 2 quarters · filed 2024-11-13 | $1.82M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $606.00K 10-Q · filed 2024-08-12 | $1.22M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $609.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |